 Sarah Rowan
Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C | 8 | 2024 | 226 | 3.080 |
Why?
| | HIV Infections | 17 | 2024 | 2470 | 2.050 |
Why?
| | Mass Screening | 7 | 2024 | 1012 | 2.000 |
Why?
| | Anti-HIV Agents | 5 | 2024 | 668 | 1.290 |
Why?
| | Pre-Exposure Prophylaxis | 5 | 2024 | 179 | 1.260 |
Why?
| | Hepacivirus | 7 | 2024 | 233 | 1.250 |
Why?
| | Drug Users | 1 | 2024 | 41 | 0.890 |
Why?
| | Substance Abuse Treatment Centers | 1 | 2020 | 42 | 0.700 |
Why?
| | Tenofovir | 2 | 2020 | 204 | 0.700 |
Why?
| | Emtricitabine | 1 | 2020 | 147 | 0.680 |
Why?
| | Continuity of Patient Care | 2 | 2019 | 253 | 0.540 |
Why?
| | Coinfection | 2 | 2021 | 120 | 0.540 |
Why?
| | HIV | 3 | 2022 | 208 | 0.520 |
Why?
| | Choice Behavior | 1 | 2016 | 155 | 0.470 |
Why?
| | Emergency Service, Hospital | 7 | 2024 | 1812 | 0.470 |
Why?
| | Patient Preference | 1 | 2016 | 169 | 0.450 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 414 | 0.440 |
Why?
| | Viral Load | 1 | 2014 | 405 | 0.410 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 207 | 0.410 |
Why?
| | Fasciola hepatica | 1 | 2012 | 5 | 0.400 |
Why?
| | Topography, Medical | 1 | 2012 | 12 | 0.400 |
Why?
| | Fascioliasis | 1 | 2012 | 7 | 0.400 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 679 | 0.390 |
Why?
| | Patient Compliance | 1 | 2014 | 524 | 0.360 |
Why?
| | Humans | 30 | 2024 | 115052 | 0.330 |
Why?
| | Adult | 16 | 2024 | 30658 | 0.330 |
Why?
| | RNA, Viral | 2 | 2022 | 567 | 0.300 |
Why?
| | Middle Aged | 13 | 2024 | 26831 | 0.270 |
Why?
| | Hospitalization | 3 | 2024 | 1755 | 0.270 |
Why?
| | Male | 19 | 2024 | 55737 | 0.260 |
Why?
| | Colorado | 3 | 2022 | 4089 | 0.260 |
Why?
| | Prevalence | 2 | 2022 | 2255 | 0.250 |
Why?
| | HIV-1 | 3 | 2021 | 768 | 0.240 |
Why?
| | Female | 17 | 2024 | 59619 | 0.230 |
Why?
| | Mycoplasma genitalium | 1 | 2023 | 2 | 0.230 |
Why?
| | Urethritis | 1 | 2023 | 3 | 0.230 |
Why?
| | Proctitis | 1 | 2023 | 5 | 0.230 |
Why?
| | Mycoplasma Infections | 1 | 2023 | 13 | 0.230 |
Why?
| | Uterine Cervicitis | 1 | 2023 | 7 | 0.220 |
Why?
| | Prospective Studies | 4 | 2023 | 6232 | 0.220 |
Why?
| | Pelvic Inflammatory Disease | 1 | 2023 | 9 | 0.220 |
Why?
| | Sexual Health | 1 | 2024 | 46 | 0.210 |
Why?
| | Trench Fever | 1 | 2022 | 3 | 0.210 |
Why?
| | Bartonella quintana | 1 | 2022 | 3 | 0.210 |
Why?
| | Endocarditis | 1 | 2022 | 32 | 0.200 |
Why?
| | Focus Groups | 1 | 2024 | 385 | 0.200 |
Why?
| | Particulate Matter | 1 | 2023 | 185 | 0.190 |
Why?
| | Housing | 1 | 2022 | 114 | 0.190 |
Why?
| | Homosexuality, Male | 2 | 2021 | 170 | 0.190 |
Why?
| | Health Services Accessibility | 2 | 2024 | 765 | 0.190 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 544 | 0.190 |
Why?
| | Safe Sex | 1 | 2020 | 20 | 0.180 |
Why?
| | Qualitative Research | 1 | 2024 | 935 | 0.170 |
Why?
| | Health Plan Implementation | 1 | 2020 | 132 | 0.170 |
Why?
| | Community Health Centers | 1 | 2019 | 54 | 0.170 |
Why?
| | Hospitals | 1 | 2024 | 582 | 0.170 |
Why?
| | Syphilis Serodiagnosis | 1 | 2019 | 3 | 0.170 |
Why?
| | Treponema pallidum | 1 | 2019 | 7 | 0.160 |
Why?
| | Darunavir | 1 | 2019 | 17 | 0.160 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 29 | 0.160 |
Why?
| | Syphilis | 1 | 2019 | 26 | 0.160 |
Why?
| | Drug Prescriptions | 1 | 2020 | 239 | 0.160 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 64 | 0.160 |
Why?
| | Administration, Oral | 1 | 2020 | 730 | 0.150 |
Why?
| | HIV Integrase Inhibitors | 1 | 2019 | 63 | 0.150 |
Why?
| | Time-to-Treatment | 1 | 2019 | 147 | 0.150 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 231 | 0.150 |
Why?
| | Public Health Surveillance | 1 | 2018 | 61 | 0.150 |
Why?
| | Treatment Outcome | 3 | 2023 | 9123 | 0.150 |
Why?
| | United States | 5 | 2024 | 12227 | 0.140 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 976 | 0.140 |
Why?
| | Reproductive Health | 1 | 2018 | 70 | 0.140 |
Why?
| | Antibodies, Viral | 1 | 2020 | 522 | 0.140 |
Why?
| | Sexual and Gender Minorities | 1 | 2019 | 138 | 0.130 |
Why?
| | Program Evaluation | 1 | 2020 | 825 | 0.130 |
Why?
| | Ribavirin | 1 | 2016 | 89 | 0.130 |
Why?
| | Follow-Up Studies | 2 | 2020 | 4420 | 0.120 |
Why?
| | Algorithms | 1 | 2021 | 1489 | 0.120 |
Why?
| | Hepatitis C, Chronic | 1 | 2016 | 152 | 0.120 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 257 | 0.110 |
Why?
| | Primary Health Care | 2 | 2023 | 1512 | 0.110 |
Why?
| | Referral and Consultation | 1 | 2018 | 633 | 0.110 |
Why?
| | Medication Adherence | 1 | 2018 | 537 | 0.110 |
Why?
| | Cohort Studies | 2 | 2019 | 4904 | 0.100 |
Why?
| | Delivery of Health Care | 2 | 2021 | 835 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1178 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 797 | 0.100 |
Why?
| | Life Cycle Stages | 1 | 2012 | 31 | 0.100 |
Why?
| | Africa | 1 | 2012 | 95 | 0.100 |
Why?
| | Population Surveillance | 1 | 2014 | 392 | 0.100 |
Why?
| | Sofosbuvir | 2 | 2022 | 54 | 0.090 |
Why?
| | Travel | 1 | 2012 | 121 | 0.090 |
Why?
| | Antiviral Agents | 1 | 2016 | 647 | 0.090 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1081 | 0.090 |
Why?
| | Risk Factors | 3 | 2021 | 8642 | 0.090 |
Why?
| | Adolescent | 3 | 2021 | 17866 | 0.080 |
Why?
| | Aged | 2 | 2019 | 19122 | 0.080 |
Why?
| | Sensitivity and Specificity | 2 | 2021 | 1715 | 0.060 |
Why?
| | Retrospective Studies | 3 | 2021 | 12548 | 0.060 |
Why?
| | Young Adult | 4 | 2024 | 10498 | 0.060 |
Why?
| | New Orleans | 1 | 2024 | 14 | 0.060 |
Why?
| | Time Factors | 1 | 2014 | 6142 | 0.060 |
Why?
| | Macrolides | 1 | 2023 | 56 | 0.050 |
Why?
| | Drug Resistance, Bacterial | 1 | 2023 | 155 | 0.050 |
Why?
| | Polyphosphates | 1 | 2022 | 33 | 0.050 |
Why?
| | Dried Blood Spot Testing | 1 | 2022 | 72 | 0.050 |
Why?
| | Intention to Treat Analysis | 1 | 2021 | 68 | 0.050 |
Why?
| | Nasopharynx | 1 | 2021 | 63 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4411 | 0.050 |
Why?
| | Community-Based Participatory Research | 1 | 2022 | 130 | 0.050 |
Why?
| | Alanine | 1 | 2020 | 104 | 0.040 |
Why?
| | Fluorenes | 1 | 2020 | 38 | 0.040 |
Why?
| | Specimen Handling | 1 | 2021 | 155 | 0.040 |
Why?
| | Protease Inhibitors | 1 | 2020 | 100 | 0.040 |
Why?
| | Saliva | 1 | 2021 | 187 | 0.040 |
Why?
| | Benzimidazoles | 1 | 2020 | 137 | 0.040 |
Why?
| | Reagins | 1 | 2019 | 1 | 0.040 |
Why?
| | Oxazines | 1 | 2019 | 26 | 0.040 |
Why?
| | Adenine | 1 | 2020 | 220 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 957 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2022 | 776 | 0.040 |
Why?
| | Chicago | 1 | 2018 | 45 | 0.040 |
Why?
| | Pyridones | 1 | 2019 | 125 | 0.040 |
Why?
| | Logistic Models | 1 | 2021 | 1839 | 0.030 |
Why?
| | Piperazines | 1 | 2019 | 313 | 0.030 |
Why?
| | Animals | 2 | 2021 | 31868 | 0.030 |
Why?
| | Sexual Partners | 1 | 2018 | 161 | 0.030 |
Why?
| | Physicians | 1 | 2024 | 772 | 0.030 |
Why?
| | Community Health Services | 1 | 2018 | 211 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 955 | 0.030 |
Why?
| | Pilot Projects | 1 | 2019 | 1375 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 1477 | 0.030 |
Why?
| | Pregnancy | 1 | 2023 | 5520 | 0.020 |
Why?
| | Child | 1 | 2019 | 18409 | 0.010 |
Why?
|
|
Rowan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|